TTrialPathMatch Me to Trials
← Back to trials
RecruitingStroke RecurrenceMyocardial InfarctionVascular Death

Cilostazol for Prevention of Recurrent Stroke Trial

Eligible age

40+ yrs

Accepts

All genders

Locations

30 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The goal of this clinical study is to learn if adding a medicine called cilostazol to usual treatment can help prevent another stroke, a heart attack, or death in patients who had a stroke caused by a blocked blood vessel, or a "mini-stroke" (also called a TIA), in the past 6 months. To determine if cilostazol is safe and effective at lowering the chance of strokes, heart attacks and deaths, the study will compare cilostazol to a placebo, a pill that looks the same as cilostazol but has no medicine in it. Participants will: * Be assigned by chance to take either cilostazol or a placebo, along with their usual medicine. * Not know which one they are taking, and neither will the study team, which keeps the results fair. * Be followed for up to 5 years to see if they have a stroke, heart attack, or major bleeding. See the Clarity study website for more information: https://www.claritystrokestudy.org/

Sponsor: Stanford University

You may qualify if…

  • ✓ 1. ≥40 years
  • ✓ 2. Ischemic stroke or high-risk TIA (ABCD2 score ≥6)
  • ✓ 3. Can be randomized within 180 days after ischemic stroke or high-risk TIA
  • ✓ 4. Treatment with single or dual antithrombotic therapy with aspirin, clopidogrel and/or ticagrelor per international and/or national guidelines
  • ✓ 5. Two or more of the following risk factors: age 65 years or older, hypertension, diabetes mellitus, history of ischemic stroke other than the qualifying event for this trial, currently smoking, peripheral arterial disease, coronary artery disease including prior MI, aortic atherosclerotic plaque ≥4 mm, ≥50% stenosis or occlusion of a major intracranial artery (ICA, M1, M2, A1, P1, vertebral, or basilar) or extracranial artery (ICA or vertebral)
  • ✓ 6. In the opinion of the site investigator, patient is medically stable, capable of participating in the trial, and willing and able to attend follow-up
  • ✓ 7. Able to receive study drug by mail and able to begin taking study drug promptly after receipt
  • ✓ 8. Provision of signed and dated informed consent form by patient or legally authorized representative

You may not qualify if…

  • ✕ 1. Atrial fibrillation, mechanical heart valve, or left ventricular assist device
  • ✕ 2. Use of prohibited medication (as specified in the MOP)
  • ✕ 3. Modified Rankin Scale 5
  • ✕ 4. Planned cardiac surgery, percutaneous coronary intervention, carotid endarterectomy or stenting (patients are eligible post-procedure)
  • ✕ 5. History of symptomatic non-traumatic intracerebral hemorrhage within last 2 years
  • ✕ 6. Known thrombocytopenia (platelet count ≤100,000 per microliter (µL))
  • ✕ 7. Severe liver dysfunction (active hepatitis or hepatic insufficiency with Child-Pugh score B or C)
  • ✕ 8. Pregnant, breast-feeding, or of child-bearing potential but not on birth control

Where it's recruiting

Alabama

Birmingham

Arizona

Chandler

California

Fontana · La Jolla · Los Angeles · Pomona …

Colorado

Grand Junction

Connecticut

New Haven

Florida

Jacksonville

Georgia

Atlanta

Illinois

Carbondale

Iowa

Iowa City

Kansas

Kansas City

Maryland

Baltimore

Source: ClinicalTrials.gov · NCT07174414 · last updated 2026-11-18

Cilostazol for Prevention of Recurrent Stroke Trial · TrialPath